Study M123
Study name | Lee LHW 2012b |
Title | Brain lipid changes after repetitive transcranial magnetic stimulation: potential links to therapeutic effects? |
Overall design | The present study was carried out to examine the effects of repetitive transcranial magnetic stimulation (rTMS) on brain lipids at the individual molecular species level using the novel technique of lipidomics. Rats were subjected to high frequency (15 Hz) stimulation of the left hemisphere with different intensities and pulses of rTMS. The prefrontal cortex, hippocampus and striatum were harvested 1 week after rTMS and lipid profiles analyzed by high-performance liquid chromatography/mass spectrometry (HPLC/MS). Rats were divided into 2 groups (n = 4 in each group): (1) control group (sham control treatment), (2) rTMS group. Rats in rTMS group were administered with either 50 pulses of TMS at 30% intensity (30% of the maximum output of the stimulator) or 200 pulses of TMS at 100% intensity per day for five consecutive days. Each pulse consisted of four 'high frequency' (15 Hz) trains i.e., rat received a total number of 200 or 800 stimuli per day. Control rats were anesthetized the same way as treated ones, but pulses were delivered at a distance of more than 10 cm from the head. |
Study Type | Type3; |
Data available | Unavailable |
Organism | Rat; Wistar rat; |
Categories of depression | Healthy individuals; Healthy individuals; Healthy individuals; |
Criteria for depression | Not reported |
Sample size | 8 |
Tissue | Central; Brain; Prefrontal cortex; Central; Brain; Hippocampus; Central; Brain; Striatum; |
Platform | MS-based; LC-MS: Agilent HPLC system coupled with Triple Quadrupole/Ion Trap mass spectrometer (4000 Q trap, Applied Biosystems, USA); |
PMID | |
DOI | |
Citation | Lee LH, Tan C, Lo Y, et al. Brain lipid changes after repetitive transcranial magnetic stimulation: potential links to therapeutic effects? Metabolomics 2012;8(1):19-33. |
Metabolite | LysoPC(16:0); LysoPC(18:0); LysoPC(18:1); LysoPC(18:2); PC(32:1); PC(36:4); PC(38:6); PC(40:6); PE(36:4); LysoPE(16:0); PC(32:0); PC(36:2); PE(38:4); Cer(d18:1/24:0); LysoPC(20:4); PC(36:3p); SM(18/16:0); Cer(d18:1/22:0); PI(40:4); Cer(d18:1/24:1); PI(40:6); PC(36:1); PC(38:3); PC(40:2p); PE(P-36:4); SM(18/24:1); SM(18/24:0); PC(40:1p); PE(P-34:1); PE(P-36:2); PE(P-36:1); PE(36:1); PE(P-38:1); LysoPE(16:0p); LysoPE(18:1p); LysoPE(18:0p); LysoPE(22:6); PC(34:2p); PC(34:1p); PC(34:0p); PC(36:4p); PC(36:2p); PC(36:1p); PC(36:0p); PC(38:4p); PC(38:3p); PC(38:2p); PC(40:4p); PC(40:3p); LysoPC(20:0/0:0); PS(36:1); PS(38:4); PS(38:3); 3-O-Sulfogalactosylceramide (d18:1/18:1 h); 3-O-Sulfogalactosylceramide (d18:1/20:0); 3-O-Sulfogalactosylceramide (d18:1/22:1); 3-O-Sulfogalactosylceramide (d18:1/22:0); 3-O-Sulfogalactosylceramide (d18:1/24:1); 3-O-Sulfogalactosylceramide (d18:1/24:0); 3-O-Sulfogalactosylceramide (d18:1/24:1 h); 3-O-Sulfogalactosylceramide (d18:1/24:0 h); PE(P-38:6); PE(40:6); PE(40:4); PE(36:3); LysoPE(20:4); PC(40:7); PS(36:2); PS(38:5); PS(40:7); PS(40:6); PS(40:5); PS(40:4); PE(34:1); PE(36:2); PE(38:6); PE(P-40:6); PE(40:5); PC(32:2); PC(34:1); PI(36:4); PI(36:3); PI(38:5); PI(38:4); PI(38:3); Lysophosphatidylserine 16:1; PS(34:1); SM(18/18:1); SM(18/18:0); PI(34:1); |
